HOUSE_OVERSIGHT_024034.jpg

2.21 MB

Extraction Summary

1
People
4
Organizations
0
Locations
0
Events
1
Relationships
3
Quotes

Document Information

Type: Financial report / investment performance summary
File Size: 2.21 MB
Summary

This document is page 23 of a confidential financial report (Control Number 257) marked with a House Oversight Bates stamp. It details the investment performance of New Leaf Ventures (I and II) and Sprout Funds in two sectors: Medical Devices and Tools, Diagnostics, & Infrastructure, as of March 31, 2014. The report lists aggregate costs, realized values, and internal rates of return (IRR) for these funds.

People (1)

Name Role Context
Fund Managers Investor
Active investor in the medical device and tools/diagnostics sectors across New Leaf and Sprout Funds.

Organizations (4)

Name Type Context
New Leaf Ventures II, L.P.
Investment fund (2008 vintage) listed in performance tables.
New Leaf Ventures I, L.P.
Investment fund (2005 vintage) listed in performance tables.
All Sprout Funds
Investment funds (1993, 1995, 1998, 2000 vintages) listed in performance tables.
House Oversight Committee
Implied by Bates stamp 'HOUSE_OVERSIGHT_024034'.

Relationships (1)

New Leaf Ventures Co-managed Sprout Funds
Both are managed by the same 'Fund Managers' and presented together in performance summaries.

Key Quotes (3)

"Combined, the Fund Managers have invested $371 million in 29 medical device companies, and have gross realizations of $394 million and a 1.82x gross realized Multiple and 9.4% gross realized IRR."
Source
HOUSE_OVERSIGHT_024034.jpg
Quote #1
"Combined, the Fund Managers have invested in 17 companies, for a total $221 million in cost."
Source
HOUSE_OVERSIGHT_024034.jpg
Quote #2
"CONTROL NUMBER 257 - CONFIDENTIAL"
Source
HOUSE_OVERSIGHT_024034.jpg
Quote #3

Full Extracted Text

Complete text extracted from the document (3,683 characters)

MEDICAL DEVICES RETURNS SUMMARY:
The Fund Managers have been an active investor in the medical device sector across the New Leaf and Sprout Funds. Combined, the Fund Managers have invested $371 million in 29 medical device companies, and have gross realizations of $394 million and a 1.82x gross realized Multiple and 9.4% gross realized IRR. Table 3 summarizes the gross realized and unrealized returns from medical device investments in each New Leaf fund and the Sprout Funds:
Table 3: Gross Medical Device Performance by Fund Group
$ amounts in millions, as of March 31, 2014
[Table Header Row 1: Gross Value | Gross Multiple | Gross IRR]
[Table Header Row 2: Deals | Total Cost | Total | Realized | Unrealized | Realized | Overall | Realized | Overall]
New Leaf Ventures II, L.P. (2008) | 5 | $72.0 | $52.5 | $1.8 | $50.6 | 0.11x | 0.73x | N/A | -9.2%
New Leaf Ventures I, L.P. (2005) | 6 | $73.3 | $146.4 | $67.3 | $79.2 | 5.64x | 2.00x | 58.8% | 15.5%
All Sprout Funds (1993, 1995, 1998, 2000) | 18 | $225.2 | $328.9 | $325.1 | $3.7 | 1.73x | 1.46x | 8.3% | 6.1%
Total | 29 | $370.5 | $527.8 | $394.2 | $133.5 | 1.82x | 1.42x | 9.4% | 6.6%
Please see the endnotes in Appendix 4 for definitions of terms and/or methodology. Note that these gross returns are for portions of each fund, broken out by investment sector subfocus. Management fees, the general partner's carried interest and other expenses are applied on a fund level and not based on individual investments or a portion of the investment portfolio. For net returns on each fund which would include these items, please see Appendix 2.
TOOLS, DIAGNOSTICS, & INFRASTRUCTURE RETURNS SUMMARY:
The Fund Managers have made investments in the tools, diagnostics, and infrastructure sector across the New Leaf and Sprout Group funds. The strategy has included predominantly later/commercial stage tools and infrastructure investments and a mix of early/development stage and later/commercial stage diagnostics companies over time. Combined, the Fund Managers have invested in 17 companies, for a total $221 million in cost. The Fund Managers have generated gross realizations of $261 million, for a 1.50x gross realized Multiple and 14.2% gross realized IRR. Table 4 summarizes the gross realized and unrealized returns from tools, diagnostics, and infrastructure investments in each New Leaf fund and the Sprout Funds:
Table 4: Gross Tools, Diagnostics, & Infrastructure Performance by Fund Group
$ amounts in millions, as of March 31, 2014
[Table Header Row 1: Gross Value | Gross Multiple | Gross IRR]
[Table Header Row 2: Deals | Total Cost | Total | Realized | Unrealized | Realized | Overall | Realized | Overall]
New Leaf Ventures II, L.P. (2008) | 3 | $31.0 | $36.1 | $0.0 | $36.1 | 0.00x | 1.16x | N/A | 4.8%
New Leaf Ventures I, L.P. (2005) | 2 | $25.7 | $1.7 | $1.7 | $0.0 | 0.06x | 0.06x | N/A | N/A
All Sprout Funds (1993, 1995, 1998, 2000) | 12 | $164.0 | $273.1 | $258.8 | $14.3 | 1.88x | 1.67x | 16.4% | 13.9%
Total | 17 | $220.7 | $310.9 | $260.5 | $50.4 | 1.50x | 1.41x | 14.2% | 11.9%
Please see the endnotes in Appendix 4 for definitions of terms and/or methodology. Note that these gross returns are for portions of each fund, broken out by investment sector subfocus. Management fees, the general partner's carried interest and other expenses are applied on a fund level and not based on individual investments or a portion of the investment portfolio. For net returns on each fund which would include these items, please see Appendix 2.
For further detail on prior performance, please refer to the Appendices and endnotes hereto.
23
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024034

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein document